References
1. Watanabe M, et al. Aliment Pharmacol Ther. 2013;38:264–273.
2. Seibold F, et al. J Crohns Colitis. 2014;8(1):56–63.
3. Carvalho PB, et al. Drugs. 2017;77(2):159–173.
4. Lamb CA, et al. British Society of Gastroenterology consensus guidelines on the
management of inflammatory bowel disease in adults. June 2019. Available at:
https://www.bsg.org.uk/wp-content/uploads/2019/12/BSG-IBD-Guidelines-2019. pdf (accessed February 2022).
5. Flourie B, et al. Aliment Pharmacol Ther. 2013;37(8):767–75.
6. Pentasa Suppositories 1 g. SmPC.
Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard By reporting side effects, you can help provide more information on the
safety of this medicine.
This information leaflet is not intended to be a substitute for medical advice. You should consult your doctor for
specific advice about your condition. You should also read through the Patient Information Leaflet, which can be
found in your PENTASA medication pack.
www.ferring.co.uk Ferring Pharmaceuticals Ltd.
Drayton Hall, Church Road,
West Drayton UB7 7PS.
Telephone: +44 (0)844 931 0050.
Date of preparation: February 2022
UK-PA-2100035